Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization

Journal of Biological Chemistry

Volumn 289, Issue 9, 2014, Pages 5499-5509

  Purushothaman, Anurag ^a   Toole, Bryan P ^b  

^a University of Alabama at Birmingham   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW STROMAL CELLS; CHONDROITIN SULFATES; CONDITIONED MEDIUM; HEMATOPOIETIC CELL; HEPATOCYTE GROWTH FACTOR; SEVERE COMBINED IMMUNODEFICIENCIES; TRANS-MEMBRANE DOMAINS; TUMOR ANGIOGENESIS;

ACTIVATION ANALYSIS; BLOOD VESSELS; BONE; CELL ADHESION; TUMORS;

CELL MEMBRANES;

ACTIVIN; CHONDROITIN SULFATE; COLLAGEN TYPE 1; HERMES ANTIGEN; LENTIVIRUS VECTOR; MESSENGER RNA; PROTEOGLYCAN; SCATTER FACTOR; SERGLYCIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE MARROW CELL; CELL ADHESION; CELL GROWTH; CELL SURFACE; CHIMERA; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; TUMOR GROWTH; UPREGULATION; VASCULARIZATION;

CD44; CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; MULTIPLE MYELOMA; PROTEOGLYCAN;

ACTIVINS; ANIMALS; ANTIGENS, CD44; BONE MARROW CELLS; CELL ADHESION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; RNA, MESSENGER; RNA, NEOPLASM; STROMAL CELLS; VESICULAR TRANSPORT PROTEINS;

EID: 84896884482     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.532143     Document Type: Article

References (46)

1. Neri, P., and Bahlis, N. J. (2012) Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr. Cancer Drug Targets 12, 776-796
2. Mitsiades, C. S., Mitsiades, N. S., Richardson, P. G., Munshi, N. C., and Anderson, K. C. (2007) Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J. Cell Biochem. 101, 950-968 (Pubitemid 47040875)
3. Sanderson, R. D., and Yang, Y. (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis 25, 149-159
4. Theocharis, A. D., Seidel, C., Borset, M., Dobra, K., Baykov, V., Labropoulou, V., Kanakis, I., Dalas, E., Karamanos, N. K., Sundan, A., and Hjerpe, A. (2006) Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J. Biol. Chem. 281, 35116-35128 (Pubitemid 46036551)
5. Kolset, S. O., and Gallagher, J. T. (1990) Proteoglycans in haemopoietic cells. Biochim. Biophys. Acta 1032, 191-211 (Pubitemid 120036338)
6. Kulseth, M. A., Kolset, S. O., and Ranheim, T. (1999) Stimulation of serglycin and CD44 mRNA expression in endothelial cells exposed to TNF-α and IL-1α. Biochim. Biophys. Acta 1428, 225-232 (Pubitemid 29352270)
7. Kolset, S. O., and Tveit, H. (2008) Serglycin-structure and biology. Cell Mol. Life Sci. 65, 1073-1085
8. Abrink, M., Grujic, M., and Pejler, G. (2004) Serglycin is essential for maturation of mast cell secretory granule. J. Biol. Chem. 279, 40897-40905 (Pubitemid 39287689)
9. Grujic, M., Braga, T., Lukinius, A., Eloranta, M. L., Knight, S. D., Pejler, G., and Abrink, M. (2005) Serglycin-deficient cytotoxic T lymphocytes display defective secretory granule maturation and granzyme B storage. J. Biol. Chem. 280, 33411-33418 (Pubitemid 41397139)
10. Kolset, S. O., and Zernichow, L. (2008) Serglycin and secretion in human monocytes. Glycoconj. J. 25, 305-311 (Pubitemid 351432853)
11. Schick, B. P., Gradowski, J. F., and San Antonio, J. D. (2001) Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood 97, 449-458 (Pubitemid 32060330)
12. Schick, B. P., and Jacoby, J. A. (1995) Serglycin and betaglycan proteoglycans are expressed in the megakaryocytic cell line CHRF 288-11 and normal human megakaryocytes. J. Cell Physiol. 165, 96-106
13. Li, X. J., Ong, C. K., Cao, Y., Xiang, Y. Q., Shao, J. Y., Ooi, A., Peng, L. X., Lu, W. H., Zhang, Z., Petillo, D., Qin, L., Bao, Y. N., Zheng, F. J., Chia, C. S., Iyer, N. G., Kang, T. B., Zeng, Y. X., Soo, K. C., Trent, J. M., Teh, B. T., and Qian, C. N. (2011) Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 71, 3162-3172
14. Niemann, C. U., Kjeldsen, L., Ralfkiaer, E., Jensen, M. K., and Borregaard, N. (2007) Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia 21, 2406-2410 (Pubitemid 350148881)
15. Humphries, D. E., Nicodemus, C. F., Schiller, V., and Stevens, R. L. (1992) The human serglycin gene. Nucleotide sequence and methylation pattern in human promyelocytic leukemia HL-60 cells and T-lymphoblast Molt-4 cells. J. Biol. Chem. 267, 13558-13563
16. Purushothaman, A., Hurst, D. R., Pisano, C., Mizumoto, S., Sugahara, K., and Sanderson, R. D. (2011) Heparanase-mediated loss of nuclear synde-can- 1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J. Biol. Chem. 286, 30377-30383
17. Purushothaman, A., Chen, L., Yang, Y., and Sanderson, R. D. (2008) Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. 283, 32628-32636
18. Purushothaman, A., Babitz, S. K., and Sanderson, R. D. (2012) Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J. Biol. Chem. 287, 41288-41296
19. Khotskaya, Y. B., Dai, Y., Ritchie, J. P., MacLeod, V., Yang, Y., Zinn, K., and Sanderson, R. D. (2009) Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J. Biol. Chem. 284, 26085-26095
20. Slomiany, M. G., Dai, L., Tolliver, L. B., Grass, G. D., Zeng, Y., and Toole, B. P. (2009) Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides. Clin. Cancer Res. 15, 7593-7601
21. Purushothaman, A., Uyama, T., Kobayashi, F., Yamada, S., Sugahara, K., Rapraeger, A. C., and Sanderson, R. D. (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 2449-2457
22. Schick, B. P. (2010) Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis. Prog. Mol. Biol. Transl. Sci. 93, 235-287
23. Meen, A. J., Øynebråten, I., Reine, T. M., Duelli, A., Svennevig, K., Pejler, G., Jenssen, T., and Kolset, S. O. (2011) Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROα/CXCL1. J. Biol. Chem. 286, 2636-2647
24. Falkowska-Hansen, B., Oynebråten, I., Uhlin-Hansen, L., and Smedsrød, B. (2006) Endocytosis and degradation of serglycin in liver sinusoidal endothelial cells. Mol. Cell Biochem. 287, 43-52 (Pubitemid 44057391)
25. Toyama-Sorimachi, N., Kitamura, F., Habuchi, H., Tobita, Y., Kimata, K., and Miyasaka, M. (1997) Widespread expression of chondroitin sulfatetype serglycins with CD44 binding ability in hematopoietic cells. J. Biol. Chem. 272, 26714-26719 (Pubitemid 27458898)
26. Toyama-Sorimachi, N., Sorimachi, H., Tobita, Y., Kitamura, F., Yagita, H., Suzuki, K., and Miyasaka, M. (1995) A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J. Biol. Chem. 270, 7437-7444
27. Toole, B. P. (2009) Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Clin. Cancer Res. 15, 7462-7468
28. Ridley, R. C., Xiao, H., Hata, H., Woodliff, J., Epstein, J., and Sanderson, R. D. (1993) Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81, 767-774 (Pubitemid 23040870)
29. Sengupta, S., Gherardi, E., Sellers, L. A., Wood, J. M., Sasisekharan, R., and Fan, T. P. (2003) Hepatocyte growth factor/scatter factor can induce an-giogenesis independently of vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 23, 69-75 (Pubitemid 36091628)
30. Iwasaki, T., Hamano, T., Ogata, A., Hashimoto, N., Kitano, M., and Kakishita, E. (2002) Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br. J. Haematol. 116, 796-802 (Pubitemid 34226998)
31. Seidel, C., Børset, M., Turesson, I., Abildgaard, N., Sundan, A., and Waage, A. (1998) Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 91, 806-812 (Pubitemid 28078282)
32. Andersen, N. F., Standal, T., Nielsen, J. L., Heickendorff, L., Borset, M., Sørensen, F. B., and Abildgaard, N. (2005) Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br. J. Haematol. 128, 210-217
33. Holt, R. U., Fagerli, U. M., Baykov, V., Rø, T. B., Hov, H., Waage, A., Sundan, A., and Børset, M. (2008) Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 93, 619-622 (Pubitemid 351536394)
34. Vallet, S., Mukherjee, S., Vaghela, N., Hideshima, T., Fulciniti, M., Pozzi, S., Santo, L., Cirstea, D., Patel, K., Sohani, A. R., Guimaraes, A., Xie, W., Chauhan, D., Schoonmaker, J. A., Attar, E., Churchill, M., Weller, E., Munshi, N., Seehra, J. S., Weissleder, R., Anderson, K. C., Scadden, D. T., and Raje, N. (2010) Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc. Natl. Acad. Sci. U.S.A. 107, 5124-5129
35. Klüppel, M. (2010) The roles of chondroitin-4-sulfotransferase-1 in development and disease. Prog. Mol. Biol. Transl. Sci. 93, 113-132
36. Bret, C., Hose, D., Reme, T., Sprynski, A. C., Mahtouk, K., Schved, J. F., Quittet, P., Rossi, J. F., Goldschmidt, H., and Klein, B. (2009) Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br. J. Haematol. 145, 350-368
37. Malla, N., Berg, E., Theocharis, A. D., Svineng, G., Uhlin-Hansen, L., and Winberg, J. O. (2013) In vitro reconstitution of complexes between promatrix metalloproteinase-9 and the proteoglycans serglycin and versican. Febs J. 280, 2870-2887
38. Abécassis, I., Olofsson, B., Schmid, M., Zalcman, G., and Karniguian, A. (2003) RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp. Cell Res. 291, 363-376 (Pubitemid 37485724)
39. Schick, B. P., and Senkowski-Richardson, S. (1992) Proteoglycan synthesis in human erythroleukaemia (HEL) cells. Biochem. J. 282, 651-658
40. Pejler, G., Abrink, M., Ringvall, M., and Wernersson, S. (2007) Mast cell proteases. Adv. Immunol. 95, 167-255 (Pubitemid 47380506)
41. Serafin, W. E., Katz, H. R., Austen, K. F., and Stevens, R. L. (1986) Complexes of heparin proteoglycans, chondroitin sulfate E proteoglycans, and [3H]diisopropyl fluorophosphate-binding proteins are exocytosed from activated mouse bone marrow-derived mast cells. J. Biol. Chem. 261, 15017-15021 (Pubitemid 17218067)
42. Zernichow, L., Abrink, M., Hallgren, J., Grujic, M., Pejler, G., and Kolset, S. O. (2006) Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-α secretion in response to lipopolysaccharide. J. Biol. Chem. 281, 26792-26801 (Pubitemid 44401708)
43. Winberg, J. O., Kolset, S. O., Berg, E., and Uhlin-Hansen, L. (2000) Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans. J. Mol. Biol. 304, 669-680 (Pubitemid 32006198)
44. Sali, A., Matsumoto, R., McNeil, H. P., Karplus, M., and Stevens, R. L. (1993) Three-dimensional models of four mouse mast cell chymases. Identification of proteoglycan binding regions and protease-specific anti-genic epitopes. J. Biol. Chem. 268, 9023-9034 (Pubitemid 23118698)
45. Pejler, G., Abrink, M., and Wernersson, S. (2009) Serglycin proteoglycan: regulating the storage and activities of hematopoietic proteases. Biofactors 35, 61-68
46. Chen, L., and Sanderson, R. D. (2009) Heparanase regulates levels of syn-decan-1 in the nucleus. PLoS One 4, e4947